Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

63.71
+0.46500.74%
Volume:173.86K
Turnover:11.06M
Market Cap:7.55B
PE:24.88
High:64.00
Open:63.05
Low:62.68
Close:63.24
52wk High:82.22
52wk Low:47.50
Shares:118.47M
Float Shares:116.00M
Volume Ratio:0.19
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.56
EPS(LYR):2.56
ROE:153.59%
ROA:22.24%
PB:154.62
PE(LYR):24.88

Loading ...

Halozyme Therapeutics Inc: Reiterating 2026 Financial Guidance

THOMSON REUTERS
·
Feb 18

Corrected-Halozyme Therapeutics Outlook FY Revenue USD 1,710-1,810 Million (Corrects Amount)

THOMSON REUTERS
·
Feb 18

Halozyme Reports Full Year 2025 Record Revenue of $1.4 Billion and Reiterates Strong 2026 Financial Guidance

THOMSON REUTERS
·
Feb 18

Why the 'HALO' trade boosting hard assets is no fluke, according to Morgan Stanley

Dow Jones
·
Feb 17

Want Stocks With AI Immunity? Think HALO -- Barrons.com

Dow Jones
·
Feb 13

Halozyme Therapeutics Inc. to Announce Financial and Operating Results

Reuters
·
Feb 11

Halozyme Therapeutics CEO Helen Torley Reports Disposal of Common Shares

Reuters
·
Feb 06

Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains

Simply Wall St.
·
Feb 01

Morgan Stanley Lifts Price Target on Halozyme Therapeutics to $78 From $75, Keeps Overweight Rating

MT Newswires Live
·
Jan 29

Halozyme Therapeutics Raises 2025, 2026 Outlooks

MT Newswires Live
·
Jan 28

GUIDANCE: (HALO) Halozyme Therapeutics Expects Full Year 2026 Non-GAAP EPS Range $7.75 - $8.25, vs. FactSet Est of $8.24

MT Newswires Live
·
Jan 28

GUIDANCE: (HALO) Halozyme Expects Full Year 2026 Revenue Range of $1.71B - $1.81B, vs. FactSet Est of $1.69B

MT Newswires Live
·
Jan 28

Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million

THOMSON REUTERS
·
Jan 28

Halozyme Therapeutics Inc FY2026 Shr View $8.19, REV View $1.69 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 28

Halozyme Therapeutics Inc Outlook 2026 Non-Gaap Diluted EPS to $7.75 - $8.25

THOMSON REUTERS
·
Jan 28

Halozyme - by 2026 End, We Project to Have 15 Partner Programs in Development; Have Signed Three or More New Drug Delivery Licensing Agreements

THOMSON REUTERS
·
Jan 28

Press Release: Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Dow Jones
·
Jan 28

Cleantek Wins Major International Contract for HALO SE Industrial Lighting Systems

TIPRANKS
·
Jan 23

Halozyme Therapeutics Inc. to Provide Updated Financial Guidance and Business Update

Reuters
·
Jan 21

Is Takeda ENHANZE Deal on Vedolizumab Reshaping the Investment Case for Halozyme Therapeutics (HALO)?

Simply Wall St.
·
Jan 20